Penicillin allergies are the most commonly reported drug allergies in the US. But do we really have to be held hostage by this when choosing antibiotic therapies? Come learn how pharmacists can play antibiotic stewardship chess to strategize alternative treatment approaches in patients with listed beta lactam allergies!
Read MoreTime to dive back into a clinical post! Plus, this one has the added bonus of also being a new drug approval post - times THREE. *mic drop* Come take a look into the world of neuroimmunology, and see what pearls you can take away for your own pharmacy practice.
Read MoreBuilding on our journal club tips from our last post, today we’re continuing down the rabbit hole of literature assessment. Clearly, it’s kind of a big deal - because no matter what venue you find yourself practicing in one day, EBM skills WILL be necessary. So come learn how to incorporate these strategies into your pharmacy practice!
Read MoreYou’re on morning rounds with the team. You have your recommendations ready. And then the attending turns to you and asks for your opinion on the new, fancy-schmancy treatment just FDA-approved. How will you know if it’s right for your patient? To the literature! It’s time to journal club (and you have to develop the skills to do so).
Read MoreEven if you don’t work specifically in oncology, chances are you’ll encounter patients with cancer in your practice-which means you may also run into mucositis. So whether you’re aiming for that PGY2 in oncology or to be your town’s favorite community practitioner, come learn what medications we use to prevent and treat this consequence of chemotherapy.
Read MoreWe’ve covered several cardiology topics over the years in previous posts, including heart failure and LVADs, but we (and our guest posters) never quite mustered the courage to tackle Acute Coronary Syndrome. Until today. Today we bring you the tl;dr overview of ACS!
Read MoreEver been totally immersed in the methods section of a study paper and wondered, “Why are there so many endpoints? What does it all MEAN?!” Yeah, us too. Which is why we’re going to try to make this essential part of trial endpoint evaluation just a smidge more clear for you.
Read MoreWith new drugs entering the market all the time and drug prices rapidly increasing, we have to ask the tough question - is the drug worth the cost? Although this question is rarely easy or straightforward to answer, we do have tools available to us to shed some light. Let tl;dr introduce you to the world of pharmacoeconomics!
Read MoreChildren are just tiny humans, right? Munchkins who function identically to adults, just on a smaller scale? NOT! Today we’re introducing you to a couple reasons why this isn’t true and then reviewing management of several classic pediatric illnesses.
Read MoreThe p-value and power are the holy grails of statistical significance, right? Let’s make sure you understand them (and how they can be exploited). This article may blow your mind. Journal club just got a whole lot more interesting…
Read MoreFirst there were regular insulins, then intermediate-acting NPH insulins, then long-acting, and most recently ultra long-acting, which is actually still a daily product. So what’s this about a possible once-weekly insulin? Wouldn’t that blow the other so-called long-acting products out of the water? Perhaps it’s time to judge with journal club.
Read MoreWe spend 4+ years as pharmacists getting our bearings for managing human pharmacotherapy. So what happens when your patient is no longer human? Are there medications on your shelves right now that you might be able to use for your humans’ furry family members?
Read More
